ArticleTransplantation and cellular therapy2026
System-level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated With High One-year Survival and Reduced Cost.
Article in Transplantation and cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Practice variation in allogeneic hematopoietic cell transplantation may contribute to preventable toxicity, nonrelapse mortality, and excess cost. We evaluated outcomes occurring with the implementation of a program-wide standardization initiative in a medium-sized program. We conducted a single-center retrospective cohort study of consecutive patients undergoing first allogeneic hematopoietic cell transplantation in 2024 during implementation of a system-level redesign. The intervention emphasized high-reliability operations through concise standard operating procedures, formal quality management, standardized recipient and donor selection, a limited conditioning regimen formulary, fluid-sparing conditioning and graft infusion practices, post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis, and an early-discharge outpatient care model. The primary endpoint was 1-year overall survival. Secondary endpoints included graft-versus-host disease-free, relapse-free survival, nonrelapse mortality, acute and chronic graft-versus-host disease, length of stay, and pharmaceutical cost. Ninety-four patients underwent a first allogeneic hematopoietic cell transplantation in 2024. One-year overall survival was 92.6%, graft-versus-host disease-free, relapse-free survival was 56%, and nonrelapse mortality was 1%. The cumulative incidence of grade II to IV acute graft-versus-host disease was 32%, with grade III to IV acute graft-versus-host disease in 5%, and chronic graft-versus-host disease requiring systemic therapy in 18% at 1 year. Median hospital length of stay was 19 days overall and 14 days among adults. Average pharmaceutical cost per patient decreased from $88,810 across the preceding 3 fiscal years to $39,019 under the redesigned care model. In this single-center cohort, implementation of a standardized, high-reliability allogeneic hematopoietic cell transplantation care model was associated with excellent 1-year survival, low nonrelapse mortality, and lower pharmaceutical cost. These findings support the potential value of disciplined operational standardization as a complement to contemporary transplant platforms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.